article thumbnail

Why Proviral DNA Drug Resistance Testing is Useful in Guiding Treatment Decisions for HIV-1 Patients

XTalks

However, the variant viral genomes will still persist in the latent reservoir as provirus and can be detected with proviral DNA testing. In contrast to HIV RNA, HIV proviral DNA remains present in a patient’s cells even during virological suppression. Proviral DNA Genotyping. HIV Drug Resistance Testing.

DNA 98
article thumbnail

Why early participant engagement is now a top priority in genetic disease research

pharmaphorum

The DNA of these so-called ‘genetic superheroes’ may contain clues about how to treat severe disease. In the next decade, ‘recontact by genotype’ to identify people at-risk or living with genetic diseases who are eligible for a new therapy or clinical trial will be a major force shaping research and healthcare.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Evolution in Hepatitis B and C Virus: Can we expect success similar to Hepatitis C in Hepatitis B as well?

Delveinsight

Hepatitis C treatment options, without a doubt, have improved significantly, including pan-genotypic medications that are used to treat all genotypes and subtypes. Typically, pan-genotypic treatments have high cure rates, few side effects, and short treatment durations (usually 8–12 weeks). and GT2 and GT3 with ribavirin.

article thumbnail

FDA Makes Low-Risk Determination for Marketing of Products from Genome-Edited Beef Cattle After Safety Review

The Pharma Data

The IGA results in the equivalent genotype (genetic make-up) and short-hair coat trait seen in some conventionally bred cattle, known as a “slick” coat. This is the FDA’s first low-risk determination for enforcement discretion for an IGA in an animal for food use. Solomon, D.V.M., director of the FDA’s Center for Veterinary Medicine.

Genome 52
article thumbnail

Biorepositories as a Guiding Resource for Research & Drug Discovery

XTalks

Through these collaborations, cohort research dataset sharing programs allow for whole-genome sequence and genotype data to be made available for independent research. The project began in 2004, in the early days of biobanking for DNA, says Dr. Bernard, and has grown tremendously since.

article thumbnail

Why a recent advancement is a giant leap for human genomics

Drug Discovery World

The remaining 8% of the genome was often referred to as the dark matter of the genome or sometimes even ‘Junk DNA’ 2. The sequencing technology relied on could only yield sequences of relatively short DNA fragments, so the assembly of sequences from highly repetitive regions was a huge challenge.

Genome 52
article thumbnail

The doors CRISPR libraries have and will open in phenotypic drug screening 

Drug Discovery World

Steve Wowk , VP, Business Unit and General Management of Integrated DNA Technologies, shared with DDW the value of CRISPR-Cas9 in drug discovery. In an effort to defend themselves against viral infection, bacterial cells capture and copy DNA fragments of bacteriophages into their genome.

Genome 52